INNOVENT BIOLOGICS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.2 HKD | -1.81% |
|
-7.49% | -17.66% |
ETFs positioned on Innovent Biologics, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.78% | 2 M€ | -19.24% | - | |
| 1.77% | 4 M€ | -27.92% | ||
| 1.09% | 1 M€ | -9.86% | - | |
| 0.68% | 2 M€ | -14.14% | ||
| 0.08% | 35 M€ | -5.85% | - | |
| 0.07% | 2,808 M€ | +5.10% | - | |
| 0.07% | 441 M€ | +3.41% | - | |
| 0.07% | 149 M€ | +0.87% | - | |
| 0.07% | 4 M€ | -4.41% | - | |
| 0.06% | 117 M€ | -0.19% | - | |
| 0.02% | 31 M€ | +2.23% | - | |
| 0.02% | 0 M€ | 0.00% | - | |
| 0.01% | 389 M€ | +7.75% | - | |
| 0.01% | 34 M€ | +2.25% | - | |
| 0.01% | 7 M€ | +1.01% | - | |
| 0.01% | 108 M€ | +2.66% | - | |
| 0.01% | 17 M€ | +2.51% | - | |
| 0.01% | 34 M€ | +7.58% | - | |
| 0.00% | 52 M€ | -0.28% | - | |
| 0.00% | 8 M€ | +0.30% | - | |
| 0.00% | 147 M€ | +4.06% | - | |
| 0.00% | 39 M€ | +5.06% | - | |
| 0.00% | 302 M€ | +4.73% | - | |
| 0.00% | 7 M€ | +0.11% | - | |
| 0.00% | 15 M€ | +6.68% |
Innovent Biologics, Inc. is a China-based biopharmaceutical company. The Company's main products include PD-1 antibody; bevacizumab (Avastin) biosimilar, IBI-305; rituximab (MabThera/Rituxan) biosimilar, IBI-301; and adalimumab (Humira) biosimilar, IBI-303.
Sector
Pharmaceuticals
Calendar
2024-08-20
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
33.15
CNY
Average target price
51.42
CNY
Spread / Average Target
+55.13%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -17.66% | 7.43B | |
| -4.40% | 86.99B | |
| +4.34% | 40.68B | |
| -23.95% | 28.61B | |
| +51.39% | 24.1B | |
| -5.09% | 17.37B | |
| -32.11% | 13.72B | |
| -5.10% | 12.49B | |
| -14.91% | 12B | |
| -4.79% | 7.94B |
- Stock Market
- Equities
- 1801 Stock
- Funds and ETFs Innovent Biologics, Inc.
